{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:46Z","timestamp":1780791106912,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.arteri.2018.11.005","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T22:17:02Z","timestamp":1549750622000},"page":"89-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tratamiento de un var\u00f3n con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9"],"prefix":"10.1016","volume":"31","author":[{"given":"Victoria","family":"Marco-Bened\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Jarauta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"P\u00e9rez-Calahorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Bea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2018.11.005_bib0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/jnnp.2009.195040","article-title":"McArdle disease: a clinical review","volume":"81","author":"Quinlivan","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.arteri.2018.11.005_bib0060","first-page":"1","article-title":"McArdle disease: a case report and review","volume":"5","author":"Leite","year":"2012","journal-title":"Int Med Case Rep J."},{"key":"10.1016\/j.arteri.2018.11.005_bib0065","first-page":"53","article-title":"McArdle disease: molecular genetic update","volume":"26","author":"Andreu","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.arteri.2018.11.005_bib0070","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3748\/wjg.v13.i18.2541","article-title":"Glycogen storage diseases: new perspectives","volume":"13","author":"\u00d6zen","year":"2007","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.arteri.2018.11.005_bib0075","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J."},{"issue":"10106","key":"10.1016\/j.arteri.2018.11.005_bib0080","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.11.005_bib0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","article-title":"Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"110","author":"Schulz","year":"2015","journal-title":"Basic Res Cardiol."},{"key":"10.1016\/j.arteri.2018.11.005_bib0090","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2018.11.005_bib0095","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of Odyssey Alternative, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2018.11.005_bib0100","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the Gauss-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491681830144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021491681830144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:44:53Z","timestamp":1762206293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021491681830144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S021491681830144X"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2018.11.005","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento de un var\u00f3n con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}